This study was conducted to determine the clinical and the prognostic degree of COX-2 expression in the liver cells of patients with chronic liver disease and hepatocellular carcinoma. A significant upregulation of COX-2 expression was noted in 47%,80% and in 89% of patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma respectively. Failure to responded to antiviral therapy was noted in 57% of patients with COX-2 expression, compared to 44% in patients with negative COX-2 expression. A significant correlation was noticed between hepatocellular COX-2 expression and fibrosis stage